To compare invasive disease-free survival (IDFS) of patients with triple-negative breast cancer (TNBC) who have either >= 1 cm residual invasive breast cancer and/or positive lymph nodes (> ypN+) after neoadjuvant chemotherapy randomized to receive 1 year of MK-3475 (pembrolizumab) adjuvant therapy compared to no MK-3475 (pembrolizumab), in both the entire study population and also in the PD-L1 positive subset.
Clinical Trial Information
Trial Contact: Morales, Leticia; Pelley, Jennifer; Jobson, Gillian S
Age Group: Adult
Phase: Drug: Phase III
Principal Investigator: Regan Derek Rostorfer, MD
Secondary Protocol No: BR006
Applicable Disease Sites: Breast Cancer